

WILLIAM WILSON TEMPLE, M.D.

Double-board Certified in Anatomical Pathology and Clinical Pathology

8350 Santa Monica Blvd #209, West Hollywood, CA 90069 | 818.359.3275

Wtemplemd12@gmail.com

CERTIFICATIONS

Diplomat of the American Board of Pathology in combined Anatomic and Clinical Pathology

LICENSURE

State of California

PROFESSIONAL EXPERIENCE

Laboratory Director, Chief Pathologist Innovative Health Diagnostics Irvine, CA	February 2021 - Present
Laboratory Director Universal Diagnostic Laboratory Inc. Van Nuys, CA	September 2010 - Present
Laboratory Director, Chief Pathologist Los Angeles Metropolitan Medical Center Los Angeles, CA	May 1998 – April 2012
Medical Director West Coast Clinical Labs Van Nuys, CA	July 2008 – July 2010
Medical Director Westcliff Medical Laboratories, Inc Burbank, CA	July 2006 – July 2008
Laboratory Director, Chief Pathologist Promise Hospital of East Los Angeles Los Angeles, CA	January 2003 – February 2005

Medical Director Health Line Clinical Laboratories, Inc Burbank, CA	September 1994 – July 2006
Laboratory Director Western Cytopathology Laboratory Burbank, CA	April 1991 – April 1994
Laboratory Director Quality Clinical Laboratories Los Angeles, CA	March 1991 – October 1993
Laboratory Director Century Community Hospital Los Angeles, CA	February 1983 – November 1986
Pathology Consultant Vandenberg Air Force Base Hospital Los Angeles, CA	May 1981 – May 1985
Pathologist Department of Pathology Martin Luther King General Hospital Los Angeles, CA	July 1980 – January 1998
Part-time Staff Pathology Group Kaiser Permanente Medical Group San Diego, CA	June 1979 – June 1980

EDUCATION

Marion Harding High School High School Valedictorian	1966 - 1969
University of Miami Bachelor of Science, "Magna Cum Laude"	1969 - 1973
Ohio State University, College of Medicine Doctor of Medicine	1973 - 1976

PUBLICATIONS

- Benirshke, K., Temple, W., and Bloor, C.: "Conjoined Twins: Nosology and Congenital Malformations", Birth Defects. 14:179-192 (1978)
- Temple, W.W. and fiber, C.M.: "Cor Biloculare and Associated Malformations", Virchows Archive. A., Pathol., AnaL, Histol., Vol. 391, pp 345-11A (1979)
- Roeske, W.R., Chen, FM., Bloor, C., Temple, W., Fleischman, J., and Yamamura, HI.: "Muscarinic-Cholinergic Receptors In Human Myocardium", Clinical Research. 24:200A, (1979)
- Temple, W., and Bloor, C.: "Cor Biloculare and Associated Malformations" Teratology. 1S:26A, (April 1977)
- PE. Grimes, W. Temple, Lori Hobbs, and A.P. Kelly: "Segmental Vitiligo: Immunologic Aberrations", Clinical Research. (April 1987)
- PE Grimes, W. Temple, Lori Hobbs, and A.P. Kelly: "Abnormal Lymphoproliferative Responses in Segmental Vitiligo" World Congress of Dermatology. West Berlin, (May 1987)
- P.E. Grimes, W. Temple, S. Gallopudi: "Lymphoproliferative Responses to Multiple Mitogens in Vitiligo", ILternal Pigment Cell Conference, Tucson, Arizona, October (1986).
- C. Perry Urown, Nagachinto, T. Cheng, F., Temple, W., Olive, N; St Louis, M.,; Kerndt, P.R.; "HIV Seroprevalence in Two Subgroups of a Los Angeles County Hospital Population", Sixth International Conference on AID.S., San Francisco, California, June (1990).

PARTIAL DESCRIPTION OF RESPONSIBILITIES

- Ongoing successful J.C.A.H. Laboratory certification for Los Angeles Metropolitan Medical Center.
- Preparation with successful initial and subsequent re-inspection for C.A.P. Certification, Health Line Clinical Labs, Burbank, CA (large, 65,000 sq. ft. reference laboratory providing laboratory services for Northern and Southern California and Phoenix, Arizona, approximately 4,000 daily patient accessions)
- Creation and maintenance of a full CAP and CLIA compliant anatomic pathology laboratory (as part of Health Line Clinical Labs). Volume: 160,000 gyn cytologies (BS% liquid based)/year, 5,200 non-gyn cytologies/year and 15,000 surgical pathology accessions/year.
- Extensive and ongoing molecular pathology (primarily liquid based cytology) including: GC-Chlamydia, Herpes 1 & 2, high and low risk HPV, Group B Strep., cystic fibrosis carrier status, and Tay-Sachs carrier status.
- Ongoing evaluation of F.IS.H. testing modalities primarily focused on urine cytology to increase sensitivity and earlier detectors of new or recurrent bladder tumors.

- Providing interpretative clinical pathology reference services for physician clients.
- Regular provision of reference and pertinent regulatory material for physician clients.
- Overall responsibility for approximately 400 115 and Lab assistant personnel.
- Ongoing education using commercially available sources as well as pertinent patient cases for CLS., cytotechnologists and client service personnel.
- Active recruitment of top, reliable C.L.S., cytotechnology, and related pathology personnel.
- Regular sales support services for acquisition and retention of physician client, (including personal visits).
- Ready availability for clients and appropriate Lab level personnel (cell and home, 24 hrs/day, 7 days/week).
- Monitoring of all aspects of pre-analytical, analytical, and post-analytical processing from routine indicators and incidents reports with particular focus on corrective actions and compliance. This is in concert with in-house dedicated QC, QA personnel.
- Current active membership in the hospital medical executive committee.
- Performance evaluations of lab supervisory personnel and cytotechnologists.
- Daily diagnostic duties in cytology and surgical pathology.
- Regular consultation with phlebotomy supervisors for personnel certification and regulatory compliance.